IBOV 177,098 ▼ 1.80% COLCAP 2,118 ▼ 0.22% MERVAL 2,738,355 ▼ 1.96% IPC MEX 70,187 ▲ 0.22% BVL PERÚ 19,767 ▲ 0.37% STOXX 50 5,861 ▲ 0.91% DAX 24,137 ▲ 0.76% CAC 8,008 ▲ 0.35% FTSE 10,325 ▲ 0.58% IBEX 17,655 ▲ 0.46% FTSE MIB 49,481 ▲ 1.00% AEX 1,010 ▲ 1.07% OMXS30 3,048 ▲ 0.05% WIG 132,379 ▲ 1.71% PSI 9,072 ▲ 0.24% SMI 13,213 ▲ 0.71% BEL 20 5,509 ▲ 0.71% S&P 500 7,444 ▲ 0.58% DOW 49,693 ▼ 0.14% NASDAQ 26,402 ▲ 1.20% RUSSELL 2,844 ▲ 0.04% TSX 34,041 ▼ 0.73% NIKKEI 62,777 ▼ 0.78% HANG SENG 26,467 ▲ 0.30% SHANGHAI 4,208 ▼ 0.81% SHENZHEN 15,894 ▼ 1.22% KOSPI 7,874 ▲ 0.39% KOSDAQ 1,173 ▼ 0.36% TWSE 41,649 ▲ 0.66% SENSEX 74,585 ▼ 0.03% NIFTY 23,442 ▲ 0.12% PSEi 5,985 ▲ 0.65% JCI 6,723 ▼ 1.98% KLCI 1,748 ▲ 0.08% STI 4,986 ▼ 0.36% SET 1,525 ▲ 0.51% ASX 200 8,617 ▼ 0.15% NZX 50 13,025 ▼ 0.29% JSE TOP 40 109,782 ▲ 0.66% EGX 30 53,416 ▼ 1.19% TASI 11,020 ▼ 0.17% USD/BRL 5.01 ▲ 2.07% USD/COP 3,783 ▼ 0.10% USD/ARS 1,392 ▲ 0.47% USD/MXN 17.17 ▼ 0.35% USD/PEN 3.42 ▲ 1.71% EUR/BRL 5.87 ▲ 1.87% EUR/USD 1.17 ▼ 0.15% GBP/USD 1.35 ▼ 0.13% USD/JPY 157.89 ▲ 0.14% USD/CNY 6.79 ▼ 0.10% USD/INR 95.86 ▲ 0.24% USD/KRW 1,493 ▼ 0.01% USD/ZAR 16.42 ▼ 0.59% USD/NGN 1,368 ▼ 0.18% USD/EGP 52.87 — 0.00% USD/TRY 45.43 ▲ 0.06% USD/RUB 73.64 ▼ 0.25% USD/CHF 0.78 ▲ 0.18% USD/CAD 1.37 ▲ 0.06% USD/HKD 7.83 ▲ 0.04% USD/SGD 1.27 ▲ 0.10% BRENT 106.15 ▲ 0.49% WTI 101.57 ▲ 0.54% GOLD 4,704 ▲ 0.13% SILVER 87.58 ▼ 1.48% COPPER 6.58 ▼ 0.82% NATGAS 2.89 ▲ 0.84% IRON ORE 161.91 ▲ 45.72% BTC 79,698 ▼ 0.97% ETH 2,264 ▼ 0.47% SELIC 14.50% IBOV 177,098 ▼ 1.80% COLCAP 2,118 ▼ 0.22% MERVAL 2,738,355 ▼ 1.96% IPC MEX 70,187 ▲ 0.22% BVL PERÚ 19,767 ▲ 0.37% STOXX 50 5,861 ▲ 0.91% DAX 24,137 ▲ 0.76% CAC 8,008 ▲ 0.35% FTSE 10,325 ▲ 0.58% IBEX 17,655 ▲ 0.46% FTSE MIB 49,481 ▲ 1.00% AEX 1,010 ▲ 1.07% OMXS30 3,048 ▲ 0.05% WIG 132,379 ▲ 1.71% PSI 9,072 ▲ 0.24% SMI 13,213 ▲ 0.71% BEL 20 5,509 ▲ 0.71% S&P 500 7,444 ▲ 0.58% DOW 49,693 ▼ 0.14% NASDAQ 26,402 ▲ 1.20% RUSSELL 2,844 ▲ 0.04% TSX 34,041 ▼ 0.73% NIKKEI 62,777 ▼ 0.78% HANG SENG 26,467 ▲ 0.30% SHANGHAI 4,208 ▼ 0.81% SHENZHEN 15,894 ▼ 1.22% KOSPI 7,874 ▲ 0.39% KOSDAQ 1,173 ▼ 0.36% TWSE 41,649 ▲ 0.66% SENSEX 74,585 ▼ 0.03% NIFTY 23,442 ▲ 0.12% PSEi 5,985 ▲ 0.65% JCI 6,723 ▼ 1.98% KLCI 1,748 ▲ 0.08% STI 4,986 ▼ 0.36% SET 1,525 ▲ 0.51% ASX 200 8,617 ▼ 0.15% NZX 50 13,025 ▼ 0.29% JSE TOP 40 109,782 ▲ 0.66% EGX 30 53,416 ▼ 1.19% TASI 11,020 ▼ 0.17% USD/BRL 5.01 ▲ 2.07% USD/COP 3,783 ▼ 0.10% USD/ARS 1,392 ▲ 0.47% USD/MXN 17.17 ▼ 0.35% USD/PEN 3.42 ▲ 1.71% EUR/BRL 5.87 ▲ 1.87% EUR/USD 1.17 ▼ 0.15% GBP/USD 1.35 ▼ 0.13% USD/JPY 157.89 ▲ 0.14% USD/CNY 6.79 ▼ 0.10% USD/INR 95.86 ▲ 0.24% USD/KRW 1,493 ▼ 0.01% USD/ZAR 16.42 ▼ 0.59% USD/NGN 1,368 ▼ 0.18% USD/EGP 52.87 — 0.00% USD/TRY 45.43 ▲ 0.06% USD/RUB 73.64 ▼ 0.25% USD/CHF 0.78 ▲ 0.18% USD/CAD 1.37 ▲ 0.06% USD/HKD 7.83 ▲ 0.04% USD/SGD 1.27 ▲ 0.10% BRENT 106.15 ▲ 0.49% WTI 101.57 ▲ 0.54% GOLD 4,704 ▲ 0.13% SILVER 87.58 ▼ 1.48% COPPER 6.58 ▼ 0.82% NATGAS 2.89 ▲ 0.84% IRON ORE 161.91 ▲ 45.72% BTC 79,698 ▼ 0.97% ETH 2,264 ▼ 0.47% SELIC 14.50%
since 2009
Thursday, May 14, 2026

Brazil Covid-19

PAHO seeks suppliers to help Brazil purchase drugs used in intubation

By · March 22, 2021 · 2 min read

RIO DE JANEIRO, BRAZIL – Close to a shortage of intubation drugs, the Brazilian government is turning to the international market in an attempt to urgently acquire the supplies and has now secured help from the Pan American Health Organization (PAHO) in the effort to quickly enable international purchases.

According to the deputy director of the institution, Jarbas Barbosa, PAHO is already looking for suppliers of the medicines of the so-called intubation kit, which can then be purchased by Brazil through the organization’s strategic fund.

The fund, which unifies purchases to secure better prices and then delivers the drugs to countries in the region, is widely used by Brazil for the purchase of antiretroviral drugs for AIDS and, according to Barbosa, has already purchased drugs used for intubation at other times.

PAHO is looking for suppliers for intubation kit drugs, which can then be purchased by Brazil. (Photo internet reproduction)

“Aware of the country’s difficulty, we are currently looking for supply alternatives with international producers,” Barbosa told Reuters.

In a meeting with the representative of PAHO in Brazil, Socorro Gross, this weekend, the organization was informed of the difficulties and has already begun contacts with producing companies.

In a statement on Monday, the Ministry of Health said it does intend to seek international purchases via PAHO.

However, despite not being in the strategies listed by the ministry, the Brazilian government also instructed its ambassadors to go in search of medicines and equipment in some countries that produce alternatives that can be quickly imported by Brazil, as confirmed to Reuters by two diplomats involved in the matter.

Read: Mato Grosso state leads ICU unavailability in Brazil; no vacancies for 15 days

The request reached the embassies urgently this weekend for the diplomats to look for suppliers willing to make immediate deliveries of medicines such as midazolam, propofol, and fentanyl, used to sedate and relax patients who need intubation.

In at least one of the countries, contacts with suppliers have already been made and there is the possibility of importation, but the information will be passed on to the Ministry of Health so that it can act.

The Ministry of Health informed on Monday that it has scheduled meetings with supplier companies in Brazil to learn about the situation of domestic production and possibly request stocks that have not yet been sold under contracts.

Last week, in a letter to President Jair Bolsonaro, the Governors’ Forum warned that in most states the medicines can last 20 days at most, and the governors are no longer finding stocks to buy. Moreover, due to demand, prices have skyrocketed in recent months.

Source: Infomoney

Read More from The Rio Times

Latin American financial intelligence, daily

Breaking news, market reports, and intelligence briefs — for investors, analysts, and expats.

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.